Evidence map›Paper›PMID 41694765›Full record

ArticleInternational journal of endocrinology2026

Ononin Sensitizes Papillary Thyroid Carcinoma Cells to Cisplatin by Repressing DNA Damage Response via E2F2.

Xian Deng, Xin Qian, Lian Cheng, Dehui Qiao, Rongjia Zhang, Xu Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xian DengDepartment of General Surgery (Thyroid Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou, China, swmu.edu.cn.ORCID https://orcid.org/0009-0006-2233-6682
Xin QianDepartment of General Surgery (Thyroid Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou, China, swmu.edu.cn.ORCID https://orcid.org/0009-0008-4775-6821
Lian ChengDepartment of General Surgery (Thyroid Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou, China, swmu.edu.cn.ORCID https://orcid.org/0000-0002-7155-898X
Dehui QiaoDepartment of General Surgery (Thyroid Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou, China, swmu.edu.cn.ORCID https://orcid.org/0009-0003-2432-3816
Rongjia ZhangDepartment of General Surgery (Thyroid Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou, China, swmu.edu.cn.ORCID https://orcid.org/0009-0000-7365-859X
Xu LiDepartment of General Surgery (Thyroid Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou, China, swmu.edu.cn.ORCID https://orcid.org/0009-0007-8762-7322

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ononin, a natural isoflavone glycoside, has demonstrated antitumor activity in several malignancies, but its role in papillary thyroid carcinoma (PTC) remains unclear. Here, we show that ononin sensitizes PTC cells to cisplatin by attenuating the DNA damage response (DDR) through the E2F2/MDC1 axis. Ononin treatment suppresses cell proliferation, colony formation, and epithelial-mesenchymal transition in PTC cell lines. Pretreatment with ononin significantly reduces the half-maximal inhibitory concentration (IC

Indexed as

cisplatinDNA damage responseE2F2ononinpapillary thyroid carcinoma

Identifiers

PMID41694765
PMCPMC12906238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.